3D Systems (DDD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Apr, 2026Executive summary
Annual Meeting scheduled for May 14, 2026, to be held virtually, with voting on key proposals and director elections.
Company focused on innovation, restructuring, and cost reduction amid macroeconomic challenges, with continued investment in R&D and targeted strategies for Healthcare and Industrial Solutions.
Significant progress made in remediating material weaknesses in internal controls, with expectation to complete remediation in 2026.
Board reduced overall debt and repositioned maturities to strengthen financial resilience.
Voting matters and shareholder proposals
Election of nine directors for one-year terms, all current directors, including exceptions for age and prior voting outcomes.
Advisory vote on executive compensation for 2025 (say-on-pay).
Ratification of Deloitte & Touche LLP as independent auditor for 2026.
Approval to amend Certificate of Incorporation to increase authorized common shares from 220M to 440M.
Approval to amend and restate the 2015 Incentive Plan, adding 4M shares and extending the term to 2036.
Board of directors and corporate governance
Board consists of nine nominees, eight of whom are independent; diverse backgrounds and skills matrix provided.
Board leadership is separated from CEO role; Chair is an independent director.
Board refreshment includes term limits and retirement age, with exceptions made for valuable expertise.
Annual self-evaluations and director stock ownership requirements in place.
Four standing committees: Audit, Compensation, Compliance/Corporate Governance/Sustainability, and Technology Applications.
Latest events from 3D Systems
- Proxy seeks approval for board elections, compensation, auditor, share increase, and incentive plan.DDD
Proxy filing26 Mar 2026 - Q4 2025 saw 16% sequential growth, margin gains, and $55M in cost savings, led by key segments.DDD
Q4 20259 Mar 2026 - Q2 revenue rose sequentially, margin improved, and full-year outlook targets breakeven Q4.DDD
Q2 202422 Jan 2026 - FDA-approved 3D printed dentures and aerospace growth position the business for major expansion.DDD
28th Annual Needham Growth Conference Virtual13 Jan 2026 - Q3 revenue fell 9% YoY to $112.9M, with a $178.6M net loss from impairment charges.DDD
Q3 202412 Jan 2026 - Aggressive cost actions and R&D focus position the business for growth in key markets.DDD
27th Annual Needham Growth Conference10 Jan 2026 - Dental and healthcare 3D printing lead growth, with cost control and new products driving profitability.DDD
Cantor Fitzgerald Global Technology Conference26 Dec 2025 - 2024 revenue hit $440M; cost cuts and Geomagic sale target break-even EBITDA by Q4 2025.DDD
Q4 20241 Dec 2025 - Annual meeting to vote on directors, pay, incentive plan, and auditor, with focus on ESG and governance.DDD
Proxy Filing1 Dec 2025